It’s forecast that obesity will affect over 80% of American men and women by 2050
“The staggeringly high discontinuation rates of GLP-1 RA should raise alarms for clinicians, policy makers, and public health experts,” said Dr Sadiya Khan, an associate professor of cardiology and preventive medicine at Northwestern University Feinberg School of Medicine and a practicing physician at Northwestern Medicine. Khan is also the lead author of an opinion piece that was published in JAMA in mid-November, written in response to the Evernorth study and KFF’s 2023 and 2024 poll data.
“While research is needed to quantify and identify the drivers, we hypothesize that there are likely many issues,” Khan continued. “First and foremost, the high cost of these therapies is likely a large barrier. Also, unlike therapies that are used to treat blood pressure or cholesterol, the perception that these are not chronic disease therapies may also be contributing. For instance, some individuals think they will stop taking them once they’ve lost weight while others are only using them cosmetically and not for management of a chronic disease.”
The authors of the opinion piece say that the findings that a lot of people stop taking GLP-1 RA drugs within a year need to be discussed more, especially in light of the benefits they provide to cardiovascular health.
“Newer, high-potency GLP-1 RAs have revolutionized the therapeutic landscape for patients living with overweight, obesity or diabetes,” said Khan. “In addition to the highly publicized weight benefits, these drugs, like semaglutide, have given the magnitude of benefit with a 20-25% reduction in cardiovascular disease events regardless of weight loss achieved.”
At the end of the day, what remains is the US’s obesity problem. The Lancet study referred to at the beginning of this article projects that a staggering 81.1% of adult males and 82.1% of adult females will be overweight and obese by 2050. Overweight and obesity need to be treated safely and effectively to avoid that worrying forecast.
Source: Northwestern University
Source link : http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=676c35d153b94c51b7f5a338e3b95407&url=https%3A%2F%2Fnewatlas.com%2Fdisease%2Fobesity%2Fus-glp-1-weight-loss-discontinuance%2F&c=8342817487178828907&mkt=en-us
Author :
Publish date : 2024-12-24 23:46:00
Copyright for syndicated content belongs to the linked Source.
